0 (0%) | 09-27 09:28 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 40.69 | 1-year : | 47.52 |
Resists | First : | 34.84 | Second : | 40.69 |
Pivot price | 32.55 ![]() |
|||
Supports | First : | 30.76 | Second : | 28.25 |
MAs | MA(5) : | 33.4 ![]() |
MA(20) : | 32.16 ![]() |
MA(100) : | 28.24 ![]() |
MA(250) : | 33.39 ![]() |
|
MACD | MACD : | 1.1 ![]() |
Signal : | 1.2 ![]() |
%K %D | K(14,3) : | 57.2 ![]() |
D(3) : | 65.1 ![]() |
RSI | RSI(14): 60.5 ![]() |
|||
52-week | High : | 47.31 | Low : | 22.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VCYT ] has closed below upper band by 28.5%. Bollinger Bands are 1.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 33.54 - 33.68 | 33.68 - 33.81 |
Low: | 32.25 - 32.4 | 32.4 - 32.55 |
Close: | 33.2 - 33.44 | 33.44 - 33.66 |
Wed, 24 Sep 2025
First-Ever Hormone Therapy Response Predictor: Veracyte's Groundbreaking Prostate Cancer Study at ASTRO 2025 - Stock Titan
Tue, 23 Sep 2025
Exchange Traded Concepts LLC Purchases 23,047 Shares of Veracyte, Inc. $VCYT - MarketBeat
Tue, 23 Sep 2025
Interesting VCYT Call Options For November 21st - Nasdaq
Tue, 23 Sep 2025
Strs Ohio Makes New Investment in Veracyte, Inc. $VCYT - MarketBeat
Sat, 30 Aug 2025
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Mon, 25 Aug 2025
Veracyte (VCYT): Reassessing Valuation After Surge in Earnings Growth and Upgraded Outlook - simplywall.st
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 79 (M) |
Shares Float | 78 (M) |
Held by Insiders | 0.5 (%) |
Held by Institutions | 109.4 (%) |
Shares Short | 8,040 (K) |
Shares Short P.Month | 9,080 (K) |
EPS | 0.34 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 15.52 |
Profit Margin | 5.5 % |
Operating Margin | 10.9 % |
Return on Assets (ttm) | 1.9 % |
Return on Equity (ttm) | 2.2 % |
Qtrly Rev. Growth | 13.8 % |
Gross Profit (p.s.) | 4.29 |
Sales Per Share | 6.09 |
EBITDA (p.s.) | 0.81 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 93 (M) |
Levered Free Cash Flow | 75 (M) |
PE Ratio | 98.35 |
PEG Ratio | 0 |
Price to Book value | 2.15 |
Price to Sales | 5.49 |
Price to Cash Flow | 28.15 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |